Pharos Vaccine Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

  • Investments
  • 1

Pharos Vaccine General Information

Description

Manufacturer of cell therapy drug products intended for emerging animal diseases, human cancers and incurable diseases. The company offers biomedicine and medical products such as vaccines and immune therapeutics.

Contact Information

Website
www.pharosvaccine.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 545, Dunchon-daero, Jungwon-gu
  • Suite 1905
  • Seongnam-si, Gyeonggi-do 13215
  • South Korea
+82 00000000
Primary Industry
Biotechnology
Parent Company
Kodi
Vertical(s)
Manufacturing
Corporate Office
  • 545, Dunchon-daero, Jungwon-gu
  • Suite 1905
  • Seongnam-si, Gyeonggi-do 13215
  • South Korea
+82 00000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pharos Vaccine Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pharos Vaccine‘s full profile, request access.

Request a free trial

Pharos Vaccine Patents

  • 29

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 11

    Granted

  • 16

    Pending

  • 000

    Expiring in next 12 mo

Pharos Vaccine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021219233-A1 Immune cells overexpressing cell signaling regulatory factor introduced from outside and use thereof Pending 14-Feb-2020 00000000000
US-20230212254-A1 Immune cells overexpressing cell signaling regulatory factor introduced from outside and use thereof Pending 14-Feb-2020 00000000000
EP-4105232-A1 Immune cells overexpressing cell signaling regulatory factor introduced from outside and use thereof Pending 14-Feb-2020 00000000000
EP-4105232-A4 Immune cells overexpressing cell signaling regulatory factor introduced from outside and use thereof Pending 14-Feb-2020 00000000000 0
US-20220042039-A1 Improved lentiviral vector Pending 28-Aug-2018 C12N15/86
To view Pharos Vaccine’s complete patent history, request access »

Pharos Vaccine Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CAR T-Cell products (Biocure Technology / Pharos Vaccine) 30-Nov-2017 00000 0000 Drug Discovery
To view Pharos Vaccine’s complete investments history, request access »

Pharos Vaccine FAQs

  • When was Pharos Vaccine founded?

    Pharos Vaccine was founded in 2011.

  • Where is Pharos Vaccine headquartered?

    Pharos Vaccine is headquartered in Seongnam-si, South Korea.

  • What industry is Pharos Vaccine in?

    Pharos Vaccine’s primary industry is Biotechnology.

  • Is Pharos Vaccine a private or public company?

    Pharos Vaccine is a Private company.

  • What is the current valuation of Pharos Vaccine?

    The current valuation of Pharos Vaccine is 000.00.

  • What is Pharos Vaccine’s current revenue?

    The current revenue for Pharos Vaccine is 000000.

  • When was Pharos Vaccine acquired?

    Pharos Vaccine was acquired on 13-Dec-2016.

  • Who acquired Pharos Vaccine?

    Pharos Vaccine was acquired by Kodi.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »